PROBIOTEARS SIGNED
Probiotic-based Ophtalmologic treatment for Bacterial and Allergic Conjunctivitis
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0PROBIOTEARS project word cloud
Explore the words cloud of the PROBIOTEARS project. It provides you a very rough idea of what is the project "PROBIOTEARS" about.
Project "PROBIOTEARS" data sheet
The following table provides information about the project.
| Coordinator |
AB BIOTICS SA
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Project website | http://www.ab-biotics.com/ |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3.2.4. (Sustainable and competitive bio-based industries and supporting the development of a European bioeconomy) 2. H2020-EU.3.2.1. (Sustainable agriculture and forestry) 3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument) 4. H2020-EU.3.2.2. (Sustainable and competitive agri-food sector for a safe and healthy diet) |
| Code Call | H2020-SMEINST-1-2016-2017 |
| Funding Scheme | SME-1 |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-10-01 to 2018-03-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | AB BIOTICS SA | ES (CERDANYOLA DEL VALLES) | coordinator | 50˙000.00 |
Map
Project objective
Conjunctivitis is a major health issue affecting more than 1100 million people worldwide. Currently, the market for bacterial & allergic conjunctivitis is mainly covered by antibiotic eye drops and ointments, which have undesired effects in the eye microbiota and contribute to increase the resistances of pathogenic strains. Other treatments such as anti-inflammatory and antihistaminic drugs have also undesired side effects and are not useful as an immediate solution.
AB-BIOTICS, a company with a broad expertise in developing functional ingredients for the pharmaceutical industry, has developed an innovative solution based on the use of probiotics. Probiotics are live micro-organisms allowing a fast and stable reestablishment of a healthy eye microbiota by providing: (1) faster anti-inflammatory and anti-histaminic effects; (2) antagonism to pathogens with no resistance risks; (3) protection against future/recurrent infections; and (4) avoidance of common side effects such as intraocular pressure rising.
The effects of the selected probiotic strains have been validated through functional in vitro and in vivo tests and its safety for ocular application has also been assessed in toxicity trials in animal models. The industrial scaling up of the strain has already been achieved and is now ready for galenic formulation.
In order to determine the key steps to bring PROBIOTEARS to the market within the next 2 years, the objectives of the presented feasibility study are: • Assess clinical ophthalmologists & users associations interest • Determine the most suitable formula for ophthalmic use • Define IPR strategy • Perform a deeper market & competitor analysis • Find key partners to carry out Supportive Clinical Trials in phase 2 • Assess Regulatory Requirements
PROBIOTEARS is a solid high-potential innovation project aligned with AB-BIOTICS’ strategy which is expected to reinforce its European & global dimension, and generate an EBITDA of 2,14M€.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROBIOTEARS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PROBIOTEARS" are provided by the European Opendata Portal: CORDIS opendata.